First US Patients Treated With Accelerated Cross-linking
The American-European Congress of Ophthalmic Surgery (ACOS) and Avedro, Inc., jointly announced that the first patients have been treated in an ACOS study of accelerated corneal collagen cross-linking (CXL) utilizing Avedro’s KXL System. Patients with keratoconus were treated at the Slade and Baker Vision Center in Houston, Texas, by Stephen Slade, MD, and Greg Parkhurst, MD. The ACOS study is a phase 3, multicenter, randomized, controlled evaluation to study accelerated CXL in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in up to 100 clinical centers across the United States.
Each of the clinical sites will exclusively use Avedro’s KXL System and proprietary riboflavin for accelerated CXL.
“I am extremely honored to be able to treat the first patients in the US ACOS CXL trial. This will be the largest trial of cross-linking to date in the United States, and will use the latest equipment,” Dr. Slade said in a news release. “The idea of stopping a blinding eye disease with this very gentle technology is most gratifying to me as a corneal surgeon. I could not be more pleased for my patients.”
Clinical sites that have installed Avedro’s equipment are now recruiting eligible patients with keratoconic and post-LASIK ectasia for treatment. A list of clinical sites is available at www.nkcf.org.
The KXL system for accelerated CXL has received the CE Mark and is commercially available in 58 countries outside the United States.